Conference Proceedings

Richter's syndrome (RS) in patients with chronic lymphocytic leukemia (CLL) on novel agent therapy.

Matthew Steven Davids, Ying Huang, Kerry Anne Rogers, Robert Stern, Jennifer R Brown, Philip A Thompson, Danielle M Brander, Alexey Valeryevich Danilov, Chaitra Shankar Ujjani, Sameer Ashok Parikh, Jacqueline Claudia Barrientos, Constantine Tam, Jennifer Ann Woyach

JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2017

Abstract

7505 Background: Novel agents (NA) targeting B cell receptor kinases and Bcl-2 have substantially improved outcomes in CLL; however, the development of RS in CLL patients (pts) on NAs has been observed, and has not been systematically evaluated. Methods: We retrospectively reviewed pts at 9 academic centers diagnosed with pathologically-confirmed RS from 2011-16. Informed consent was provided through IRB-approved protocols. Descriptive statistics were utilized and overall survival (OS) was calculated from RS diagnosis (dx) to death or last follow-up by Kaplan-Meier. Results: 71 pts who developed RS on NAs for CLL were identified. Median age at CLL dx was 55 yrs (range 21-82), median of 3 th..

View full abstract